Antithrombotic therapy after transcatheter aortic valve implantation.
Antonio GrecoMarco SpagnoloDavide CapodannoPublished in: Expert review of medical devices (2022)
Initial experience with antithrombotic therapy after TAVI was derived from percutaneous coronary intervention practice. Accruing evidence in the field led to the current monotherapy paradigm, which prioritizes oral anticoagulant and single antiplatelet therapy in patients with or without an established indication for long-term anticoagulation, respectively. Future studies will investigate the role of alternative antithrombotic strategies to improve clinical outcomes of TAVI patients by minimizing both thrombotic and bleeding complications.
Keyphrases
- transcatheter aortic valve implantation
- atrial fibrillation
- percutaneous coronary intervention
- antiplatelet therapy
- aortic stenosis
- aortic valve
- ejection fraction
- aortic valve replacement
- acute coronary syndrome
- st segment elevation myocardial infarction
- end stage renal disease
- acute myocardial infarction
- st elevation myocardial infarction
- chronic kidney disease
- transcatheter aortic valve replacement
- coronary artery bypass grafting
- venous thromboembolism
- coronary artery disease
- heart failure
- stem cells
- healthcare
- newly diagnosed
- primary care
- prognostic factors
- left ventricular
- open label
- peritoneal dialysis
- randomized controlled trial
- combination therapy
- bone marrow
- coronary artery bypass
- current status
- risk factors
- cell therapy